ARCHIVES

Drug Shortage A Boon For Levoleucovorin; Price Is 60 Times Higher Than Leucovorin

This article is from The Cancer Letter archive.

Vol. 35 No. 02 | January 16, 2009

Download PDF Visit The Full Archive

Related Articles

GPC Biotech’s Satraplatin Fails To Extend Survival In Hormone-Refractory Prostate Cancer.

November 2, 2007

In Brief: Calabresi Named To President’s Cancer Panel; Mays Leaves NCI Technology Office For IVAX

May 5, 1995

Resolutions Urge Doubling Of NIH Budget From ’98 Level.

March 9, 2001

Low Total Cholesterol Linked To Higher Risk Of Cancer; Higher HDL Associated With Decreased Risk Of Cancer

November 27, 2009

Tivozanib Trumps Sorafenib In 1st-Line Renal Cancer Study

May 25, 2012

Congressman Carter To Address ACCC Annual Conference

December 3, 1976